Supplementary Table 2 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Dataset en
Authors
HK
Hojabr Kakavand
JW
James S. Wilmott
AM
Alexander M. Menzies
Abstract
1 min read
<p>Supplementary Table 2. The percentage of PD-L1 expressing tumor/immune cells and the intensity of staining in these samples used to derive the immuno-reactive score (IRS) for the 40 patients. *Immune cells= lymphocytes and macrophages.</p>
Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A Scolyer
Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A Scolyer
Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A Scolyer
Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A Scolyer
Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A Scolyer
Discussion(0)
No comments yet. Be the first to comment.